News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Withdraws Application for Wider Tyverb Use


2/16/2012 8:22:00 AM

The European Medicines Agency said on Thursday that GlaxoSmithKline had withdrawn its application to widen use of its cancer drug Tyverb after regulators said it would be difficult to make a judgment without an active controlled trial. The British drugmaker had wanted to extend the authorisation of the cancer drug, known generically as lapatinib, for use in combination with the chemotherapy drug paclitaxel for some breast cancer patients. Tyverb was approved in Europe in 2008 for use in combination with two other drugs - capecitabine and an aromatase inhibitor - for certain patients.

Read at Reuters
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES